Podcast
Questions and Answers
Which of the following targeted therapies is associated with differentiation syndrome as a significant adverse effect?
Which of the following targeted therapies is associated with differentiation syndrome as a significant adverse effect?
- Selinexor
- Enasidenib (correct)
- Ibrutinib
- Idelalisib
A patient undergoing CAR-T cell therapy develops cytokine release syndrome (CRS). Which CAR-T therapy target is LEAST likely the cause, given their known specificities?
A patient undergoing CAR-T cell therapy develops cytokine release syndrome (CRS). Which CAR-T therapy target is LEAST likely the cause, given their known specificities?
- CD19
- BCMA
- CD30 (correct)
- CD22
Which of the following mechanisms of action is correctly paired with its respective agent used in cancer therapy?
Which of the following mechanisms of action is correctly paired with its respective agent used in cancer therapy?
- Thalidomide: Inhibits telomerase activity
- Hydroxyurea: Depletes asparagine from plasma
- Asparaginase: Inhibits ribonucleotide reductase
- Arsenic trioxide: Degrades PML-RAR-α (correct)
A researcher is investigating novel therapies to target B-cell malignancies. Which of the following targets, when bound by a monoclonal antibody, is most likely to directly inhibit B-cell receptor signaling?
A researcher is investigating novel therapies to target B-cell malignancies. Which of the following targets, when bound by a monoclonal antibody, is most likely to directly inhibit B-cell receptor signaling?
A patient with relapsed/refractory multiple myeloma is being considered for targeted therapy. Based on the provided information, which of the following targets is most relevant for this patient's treatment?
A patient with relapsed/refractory multiple myeloma is being considered for targeted therapy. Based on the provided information, which of the following targets is most relevant for this patient's treatment?
A patient undergoing photodynamic therapy with methoxsalen is being educated about the treatment. Which mechanism of action should the healthcare provider emphasize?
A patient undergoing photodynamic therapy with methoxsalen is being educated about the treatment. Which mechanism of action should the healthcare provider emphasize?
Which of the following cellular effects are associated with tretinoin (ATRA) treatment in Acute Promyelocytic Leukemia (APL)?
Which of the following cellular effects are associated with tretinoin (ATRA) treatment in Acute Promyelocytic Leukemia (APL)?
A patient is prescribed pembrolizumab for cancer treatment. What is the primary mechanism of action of this drug?
A patient is prescribed pembrolizumab for cancer treatment. What is the primary mechanism of action of this drug?
A patient is scheduled to receive rituximab as part of their treatment regimen. What is the target of the rituximab monoclonal antibody?
A patient is scheduled to receive rituximab as part of their treatment regimen. What is the target of the rituximab monoclonal antibody?
A patient develops peripheral neuropathy during cancer treatment. Which of the following monoclonal antibodies is most likely to be the cause?
A patient develops peripheral neuropathy during cancer treatment. Which of the following monoclonal antibodies is most likely to be the cause?
A patient experiences cytokine release syndrome (CRS) after cancer treatment. Which class of antibodies is most likely responsible for this adverse effect?
A patient experiences cytokine release syndrome (CRS) after cancer treatment. Which class of antibodies is most likely responsible for this adverse effect?
A patient with a specific genetic mutation requires a selective inhibitor to block the Philadelphia chromosome. Which of the following STIs is most appropriate for this patient?
A patient with a specific genetic mutation requires a selective inhibitor to block the Philadelphia chromosome. Which of the following STIs is most appropriate for this patient?
A patient receiving chemotherapy develops signs of increased DNA condensation. Which class of drugs could be used to counteract this effect?
A patient receiving chemotherapy develops signs of increased DNA condensation. Which class of drugs could be used to counteract this effect?
Blinatumomab targets which of the following proteins on cancer cells and T-cells?
Blinatumomab targets which of the following proteins on cancer cells and T-cells?
Which of the following targeted therapies is used to treat multiple myeloma by targeting CD38 on myeloma cells and Fc on NK cells?
Which of the following targeted therapies is used to treat multiple myeloma by targeting CD38 on myeloma cells and Fc on NK cells?
Which kinase is NOT a target of the listed mutant kinase receptor inhibitors?
Which kinase is NOT a target of the listed mutant kinase receptor inhibitors?
Which of the following targeted therapies is used in cancers with Mutant IDH1 or 2?
Which of the following targeted therapies is used in cancers with Mutant IDH1 or 2?
Which of the following cellular therapies targets BCMA?
Which of the following cellular therapies targets BCMA?
Which of the following conditions is NOT explicitly listed as a cancer type treated by the drugs listed?
Which of the following conditions is NOT explicitly listed as a cancer type treated by the drugs listed?
Which of the following targets of the listed miscellaneous STIs does NOT play a role in epigenetic regulation?
Which of the following targets of the listed miscellaneous STIs does NOT play a role in epigenetic regulation?
A patient with relapsed/refractory multiple myeloma has disease progression after treatment with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody. Which of the following would be the MOST appropriate next targeted therapy?
A patient with relapsed/refractory multiple myeloma has disease progression after treatment with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody. Which of the following would be the MOST appropriate next targeted therapy?
Flashcards
Mutant IDH Blockers
Mutant IDH Blockers
Drugs targeting mutant isocitrate dehydrogenase with a risk of differentiation syndrome.
CAR-T Therapy
CAR-T Therapy
A treatment that modifies T-cells to target cancer, associated with Cytokine Release Syndrome (CRS).
Asparaginase
Asparaginase
An enzyme that depletes asparagine from plasma, used in treating certain leukemias.
Hydroxyurea
Hydroxyurea
Signup and view all the flashcards
Thalidomide
Thalidomide
Signup and view all the flashcards
Multiple Myeloma
Multiple Myeloma
Signup and view all the flashcards
B-cell Lymphoma
B-cell Lymphoma
Signup and view all the flashcards
CD19
CD19
Signup and view all the flashcards
BCMA
BCMA
Signup and view all the flashcards
Imatinib
Imatinib
Signup and view all the flashcards
CAR T-cell Therapy
CAR T-cell Therapy
Signup and view all the flashcards
Venetoclax
Venetoclax
Signup and view all the flashcards
Proteasome Inhibitors
Proteasome Inhibitors
Signup and view all the flashcards
Photodynamic therapy
Photodynamic therapy
Signup and view all the flashcards
Retinoids
Retinoids
Signup and view all the flashcards
PD-1 inhibitors
PD-1 inhibitors
Signup and view all the flashcards
Anti-CD20 mAbs
Anti-CD20 mAbs
Signup and view all the flashcards
BITE antibodies
BITE antibodies
Signup and view all the flashcards
JAK inhibitors
JAK inhibitors
Signup and view all the flashcards
HDAC inhibitors
HDAC inhibitors
Signup and view all the flashcards
Study Notes
Photodynamic Therapy
- Methoxsalen (Uvadex) inhibits DNA synthesis and damages DNA.
Retinoids
- Tretinoin (ATRA) activates PML-RAR, inhibiting differentiation, and increases normal white blood cells.
- RA-APL syndrome/leukocytosis increases white blood cells and immune system activity.
- Bexarotene activates RXR.
PD-1/T-cell Checkpoint Inhibitors
- Pembrolizumab or Nivolumab block immune cell (T-cell) inhibition via PD-1.
- Increase immune system response.
Anti-CD19 mAbs/CD20 mAbs
- -tamab, -tuximab, -tumomab, -tuzumab
- CD19: tafasitamab, loncastuximab.
- CD20 (Type I): Rituximab, ofatumumab.
- CD20 (Type II): obintuzumab, ibritumomab.
Anti-CD22 mAbs
- Inotuzumab ozogamicin
Anti-CD30 or CD79b mAbs
- Brentuximab vedotin inhibits tubulin polymerization, causing peripheral neuropathy.
Anti-CD38 or SLAMF mAbs
- -tuximab, -tumumab
BITE antibodies
- -tumomab, -tuzumab, -tamab
- Cytokine release syndrome (CRS) and neurotoxicity.
- CD3 & CD19: blinatumomab, mosunetuzumab
- CD3 & BCMA: teclistamab, talquetamab
STI's that block JAK/BTK
- Fedratinib, pacritinib, ruxolitinib block JAK.
- Ibrutinib, acalabrutinib block BTK.
Block Ph & c-KIT
- -a/-o/-utinib (except fedratinib) block Ph & c-KIT.
- Asciminib targets Ph specific.
Block FLT3
- Midostaurin, gilteritinib, quizartinib (Vanflyta) block FLT3.
SMO Blockers
- Glasdegib blocks SMO.
Block PKB at PI3K
- Idelalisib, duvelisib block PKB at PI3K.
Black Protein Synthesis
- Omacetaxine mepesuccinate (Synribo) binds to ribosomes.
Proteasome Inhibitors
- Bortezomib, carfilzomib, ixazomib are proteasome inhibitors.
Block DNA Condensation
- Romidepsin, vorinostat, belinostat, panobinostat block DNA condensation via HDAC.
- Tazemetostat block DNA condensation via HMT.
Block BCL-2
- Venetoclax blocks BCL-2.
Mutant IDH Blockers
- Ivosidenib, enasidenib, olutasidenib are Mutant IDH Blockers, inducing differentiation syndrome.
Inhibit Nuclear Transport
- Selinexor inhibits nuclear transport (exportin 1).
Block Menin/Aberrant Transcription
- Revumenib blocks menin/aberrant transcription.
Inhibit Telomerase
- Imetelstat (Rytelo) inhibits telomerase.
CAR-T Therapy
- Lisocabtagene maraleucel targets CD19 (except idecabtagene vicleucel and ciltabtagene autoleucel).
- Targets BCMA.
Misc. Agents
- Hydroxyurea inhibits ribonucleotide reductase, inhibiting DNA synthesis.
- Asparaginase depletes asparagine from plasma.
- Arsenic trioxide degrades PML-RAR-a, causing differentiation.
Thalidomide
- Increases IL-2 & Interferon gamma, activating NK cells, inhibiting myeloid cell growth.
Summary of Protein Drugs with Immune Cell Targets
- Various drugs targeting different immune cells (e.g., CD19, CD20, etc) and their corresponding cancers.
mAbs/STIs Summary of Miscellaneous STIs
- Various drugs targeting different targets (e.g., Mutant IDH1 or 2, P13-kinase, Proteasome, etc).
Miscellaneous Antineoplastic Agents
- Drugs like hydroxyurea, asparaginase, and arsenic trioxide with their mechanisms of action and uses.
Summary of Recovery Agents
- Various drugs stimulating endogenous agonists for different conditions (e.g., neutropenia, anemia, thrombocytopenia).
Summary of Anti-Emetics
- Various groups of anti-emetic drugs including 5-HT3 and NK1 antagonists, D2 antagonists, glucocorticoids, and H1 and M1 antagonists, and their uses for nausea/vomiting.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Related Documents
Description
This lesson covers several cancer treatments including photodynamic therapy, retinoids and monoclonal antibodies (mAbs). It details specific drugs like methoxsalen, tretinoin, pembrolizumab and rituximab. The lesson also explains treatment targets like CD19, CD20, CD22, CD30, CD38 and SLAMF.
